Data from a post-hoc analysis show that use of ixekizumab improves signs and symptoms of difficult-to-treat psoriatic arthritis (PsA) patients who previously failed to respond to 1 or 2 TNF inhibitor (TNFi) therapies.
“PsA is a progressive, chronic inflammatory disease that is often treated with TNFi when conventional treatments have failed. We have learned from rheumatoid arthritis (RA) and PsA that patients with an inadequate response to the first TNFi generally have a decreased response to subsequent TNFi,” said Dr Amanda Gellett (Eli Lilly, USA). In addition, in a substantial proportion of patients, TNFi therapy might be contra-indicated or not tolerated. “Also, nearly 40% of the patients in this population switched TNFis as part of their routine care, and that was mainly due to lack of efficacy,” added Dr Gellett. Therefore, therapies with an alternative mechanism of action in PsA are clinically important.
The anti–interleukin-17 drug ixekizuma...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Short Methotrexate Stop Is Safe in Patients with RA Next Article
Peficitinib Likely Efficacious and Safe »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.